COX-2 Overexpression in Schneiderian Papillomas.
Jeffrey D SuhKevin T HurElisabeth H FerenceDavid D LamAndrew FongAdrian J CorreaBozena WrobelPublished in: Allergy & rhinology (Providence, R.I.) (2020)
COX-2 was overexpressed in 58.2% of SP cases, and strongly positive in 22.4% of cases, compared to no positive staining among controls. No significant differences in COX-2 expression were observed between SP subtypes or recurrent tumors. Further studies are warranted to evaluate COX-2 as a possible therapeutic target in tumors that overexpress the enzyme.